{"id":88050,"date":"2025-12-18T15:20:13","date_gmt":"2025-12-18T15:20:13","guid":{"rendered":"https:\/\/www.newsbeep.com\/us-fl\/88050\/"},"modified":"2025-12-18T15:20:13","modified_gmt":"2025-12-18T15:20:13","slug":"usf-health-researchers-seeking-better-safer-alternatives-to-current-opioid-drugs","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us-fl\/88050\/","title":{"rendered":"USF Health researchers seeking better, safer alternatives to current opioid drugs"},"content":{"rendered":"<p>Researchers at USF Health are making dramatic strides in understanding how new opioid<br \/>\n                  compounds work inside the body to provide pain relief, offering greater hope that<br \/>\n                  new classes of these drugs may eventually be used to relieve pain without potentially<br \/>\n                  deadly side effects.<\/p>\n<p>The research team\u2019s latest study, \u201c<a href=\"https:\/\/www.nature.com\/articles\/s41586-025-09880-5\" target=\"_blank\" rel=\"noopener nofollow\">GTP release-selective agonists prolong opioid analgesic efficacy<\/a>,\u201d is published today in Nature, one of the leading peer-reviewed medical journals. \u00a0This study is accompanied by<br \/>\n                  a related manuscript, \u201c<a href=\"https:\/\/www.nature.com\/articles\/s41467-025-66516-y\" target=\"_blank\" rel=\"noopener nofollow\">Characterization of the GTP\u03b3S release function of a G protein-coupled receptor,<\/a>\u201d also published today in Nature Communications. \u00a0<\/p>\n<p>\u201cOur overarching research aims to understand how opioids work so that we can ultimately<br \/>\n                  provide safer options for chronic pain and develop therapies for opioid use disorders,\u2019\u2019<br \/>\n                  said the study\u2019s senior author, Laura M. Bohn, PhD, senior associate dean for Basic<br \/>\n                  and Translational Research and professor of Molecular Pharmacology and Physiology<br \/>\n                  in the USF Health Morsani College of Medicine.<\/p>\n<p>The papers describe evolving work on a collection of pain-relieving compounds that,<br \/>\n                  like morphine and other drugs, provide relief by binding to what are called mu opioid<br \/>\n                  receptors \u2014 specialized proteins in nerve cells that, when opioids bind to them, can<br \/>\n                  block the transmission of pain signals.<\/p>\n<p>When morphine-like analgesics bind to these receptors, \u00a0they also create unwanted<br \/>\n                  side effects that can be dangerous, such as breathing suppression. Dr. Bohn and her<br \/>\n                  team are developing newer compounds that provide pain relief without inducing dangerous<br \/>\n                  and unwanted side-effects that have driven opioid-related overdose and deaths. \u00a0The<br \/>\n                  current studies uncover new ways that the receptor functions when bound to opioid<br \/>\n                  analgesics.<\/p>\n<p>While the current studies may not directly lead to a new drug in the clinic immediately,<br \/>\n                  they could lead to a better understanding of how receptors work, said Edward Stahl,<br \/>\n                  PhD, assistant professor of Molecular Pharmacology and Physiology in the Morsani College<br \/>\n                  of Medicine and also a corresponding author on the study, which was funded by the<br \/>\n                  National Institutes of Health.<\/p>\n<p>\u201cOur manuscripts describe a unique way that drugs can control receptors,\u2019\u2019 Dr. Stahl<br \/>\n                  said. \u201cFundamentally, knowing more about how receptors work is the first step in understanding<br \/>\n                  how to drug them and how to drug them safer. If this research is further validated,<br \/>\n                  it would add to our textbook knowledge of how receptors function and, more importantly,<br \/>\n                  to our ability to treat human health and disease.\u2019\u2019<\/p>\n<p>The team\u2019s research addresses how certain drugs, when binding to a receptor, start<br \/>\n                  a chain reaction that ultimately leads to biological responses in a person\u2019s body.<br \/>\n                  Prolonged use of pain-relieving opioids such as morphine, oxycodone, and fentanyl<br \/>\n                  can have harmful and even deadly results, particularly respiratory suppression. Another<br \/>\n                  major challenge is how to slow down or stop what scientists call \u201ctolerance development\u2019\u2019<br \/>\n                  of these drugs.<\/p>\n<p>\u201cWe\u2019ve found that the first step of the chain reaction is reversible, and that some<br \/>\n                  drugs can favor a reverse reaction over the forward reaction,\u2019\u2019 Dr. Bohn said. \u201cWe\u2019ve<br \/>\n                  studied two new chemicals that strongly favor the reverse cycle and, when administered<br \/>\n                  at non-effective doses, can enhance morphine and fentanyl-induced pain relief while<br \/>\n                  not enhancing the respiratory suppression effects.\u2019\u2019<\/p>\n<p>These prototype molecules are not considered drug candidates because they do suppress<br \/>\n                  respiration at high doses and they haven\u2019t been tested for toxicity or other side<br \/>\n                  effects of opioids, Dr. Bohn said. However, she said, \u201cthey do provide the framework<br \/>\n                  for building new drugs.\u2019\u2019\u00a0<\/p>\n<p>Dr. Bohn\u2019s lab previously discovered a compound called SR-17018 that does not produce<br \/>\n                  respiratory suppression or tolerance. SR-17018 activates the same pain-relieving receptor<br \/>\n                  as morphine, oxycodone and fentanyl. However, it binds to opioid receptors in a different<br \/>\n                  way from those drugs, leaving the receptor open and available to the body\u2019s own natural<br \/>\n                  pain-relieving substances.<\/p>\n<p>While SR-17018 prefers the \u201creverse direction,\u201d it has other features that researchers<br \/>\n                  believe lead to its improved profile. For this reason, Dr. Bohn said, \u201cwe will be<br \/>\n                  using our new findings to improve upon SR-17018.\u2019\u2019<\/p>\n<p>Ongoing research could lead to the development of drugs for other receptors that can<br \/>\n                  be activated in the \u201creverse\u201d direction. For example, the serotonin 1A receptor is<br \/>\n                  shown to have this property, Bohn said, and \u201cthis is an important drug target in neuropsychiatric<br \/>\n                  disorders, including depression and psychosis.\u2019\u2019<\/p>\n<p>Dr. Bohn\u2019s research is especially significant in the larger context of the ongoing<br \/>\n                  public health crisis created by opioid dependency and misuse. Studies show that 68<br \/>\n                  percent of all overdose deaths in 2024 involved opioids, of which 88 percent were<br \/>\n                  due to fentanyl and other synthetic opioid compounds.<\/p>\n<p>An internationally recognized leader in molecular pharmacology and neurobiology, Dr.<br \/>\n                  Bohn recently joined USF Health. She is best known for her pioneering studies on G<br \/>\n                  protein\u2013coupled receptors (GPCRs) \u2014 the most abundant class of drug targets in the<br \/>\n                  human body.<\/p>\n<p>Her laboratory has made landmark discoveries in opioid receptor signaling bias, showing<br \/>\n                  how selective activation of intracellular pathways can manage pain without respiratory<br \/>\n                  depression or tolerance development. This research adds to the understanding of opioid<br \/>\n                  pharmacology and the search for next-generation, non-addictive pain therapeutics.<\/p>\n<p>\u2014 photo by Freddie Coleman, USF Health Communications\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Researchers at USF Health are making dramatic strides in understanding how new opioid compounds work inside the body&hellip;\n","protected":false},"author":2,"featured_media":88051,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[135,137,136],"class_list":["post-88050","post","type-post","status-publish","format-standard","has-post-thumbnail","category-tampa","tag-tampa","tag-tampa-headlines","tag-tampa-news"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us-fl\/wp-json\/wp\/v2\/posts\/88050","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us-fl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us-fl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-fl\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-fl\/wp-json\/wp\/v2\/comments?post=88050"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us-fl\/wp-json\/wp\/v2\/posts\/88050\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-fl\/wp-json\/wp\/v2\/media\/88051"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us-fl\/wp-json\/wp\/v2\/media?parent=88050"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-fl\/wp-json\/wp\/v2\/categories?post=88050"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-fl\/wp-json\/wp\/v2\/tags?post=88050"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}